Proud to share results of ph3 RCT in 495 pts w/ borderline resectable oral ca. OS with TPF > TP. Half pts who underwent surgery were alive at 5 yr vs 5% for who didnt ejcancer.com/article/S0959-… OncoAlert Dr (Prof). Vijay Patil Dr. Pankaj Chaturvedi Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO #hncsm #headandneckcancer

the largest study (495) in borderline resectable head and neck cancers. 5-year OS in TP was 18.5% and TPF=23.9%; P=0.015. Gives the importance giving proper TPF regimen. ashayoncology Santam Chakraborty Dr Akhil Kapoor ImmunoACT Dr Atul Sharma Nandini Menon.

Finally #Borderlineresectable has arrived. RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as NACT in borderline resectable oral cancer - EJC ejcancer.com/article/S0959-… Prof. Anil D'Cruz Christina Henson, MD The ASCO Post Vanita Noronha, MBBS MD DM TMH Medical Oncology Alumni Ezra Cohen Head and Neck Cancer International Group

Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer - European Journal of Cancer ejcancer.com/article/S0959-…

Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients.
Age, regimen, response to NACT and surgical resection were significant predictors of overall survival Tata Memorial Hospital
ACTREC-TMC
sciencedirect.com/science/articl…

Long-term outcomes of neo-adjuvant chemotherapy on borderline resectab... sciencedirect.com/science/articl…. 10 year results with Bordeline oral cavity cancer Ezra Cohen Vanita Noronha, MBBS MD DM Nandini Menon

Resistance to metronomic . Whole exome sequencing uncovers HRAS mutations as potential mediators ... sciencedirect.com/science/articl… Vanita Noronha, MBBS MD DM Nandini Menon Ezra Cohen Santam Chakraborty

The Indian oncology extravaganza 😍😇 #oncology #ICC2023

Honored and privileged to deliver a Plenary Talk on Precision Management of Oligometastatic NSCLC at #WCLC23 #IASLC Rima Pathak MD Amiya Agrawal MD TMC Radiation Oncology Tata Memorial Hospital Devayani Niyogi Sabita Jiwnani Andrea Bezjak RadOncResearch Dr (Prof). Vijay Patil

⁦Anil Tibdewal⁩ speaks on the challenges of #lungcancer treatment in LMIC. Eagerly await data from his trial on TKI +/- SABR in oligometastasis #lungcancer #WCLC23 @iaslc ⁦Tata Memorial Hospital⁩ #equity

🙏🏽 ⁦RadOncResearch⁩ for asking me to chair the health services research track #WCLC23 w Dr Huang. Fantastic talks by all speakers ⁦Anne Fraser⁩ ⁦Dr Anne-Marie Baird⁩ ⁦gilberto lopes⁩ ⁦Nandini Menon⁩ ⁦ML Yap⁩ ⁦Susan Harden⁩ ⁦IASLC⁩ 👏🏽👏🏽👏🏽

So proud of my colleague Anil Tibdewal who’s presenting on #PrecisionManagement of #Oligometastatic disease in #LungCancer at the #LMIC plenary session on the final day of #WCLC23 IASLC Tata Memorial Hospital TMC Radiation Oncology Naveen Mummudi 👏👏👏

Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly-diagnosed glioblastoma led by Dr Tejpal Gupta academic.oup.com/noa/article/do… Tata Memorial Hospital ACTREC-TMC SNO EANO

the study gives an important message that if something works in pallaitive setting. It is not necessary that it will work in curative setting.

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation | More nice work from Tata Memorial ⁦Journal of Clinical Oncology⁩ ascopubs.org/doi/abs/10.120…

clinresonc.eu Thank you for higlighting our phase 3 randomised trial, DOI: 10.1200/JCO.22.00980 Journal of Clinical Oncology Vanita Noronha, MBBS MD DM Nandini Menon Amol Patel Dr Ameya Puranik Dr Rakesh katna Arjun Singh Shivakumar Thiagarajan Prof. Anil D'Cruz Prathamesh Pai Santam Chakraborty

Phase III Randomized Trial for Use of Docetaxel in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. Vanita Noronha, MBBS MD DM Amol Patel Nandini Menon Ezra Cohen Journal of Clinical Oncology P.D.Hinduja Hospital Khar Tata Memorial Hospital Robert Haddad ascopubs.org/doi/abs/10.120…

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation ascopubs.org/doi/abs/10.120…

1st National Molecular Tumor & precision board met today at 8:00 AM on 26th January 2023. Holistic management with molecular report understanding, Pathway analysis, genetic implications and many more. P.D.Hinduja Hospital Khar P. D. Hinduja Hospital Vanita Noronha, MBBS MD DM Sewanti Limaye 🇮🇳🇺🇸 Nandini Menon